ADHD Research Briefing: Week of July 3 to July 9, 2026
Five studies, three minutes. Researchers are questioning the diagnostic boxes, and the news for women keeps reshaping who gets seen and safely treated.
The theme this week: Researchers are questioning the boxes. The standout new paper argues ADHD isn't a tidy category at all: it blurs into autism and learning differences along one shared spectrum. Meanwhile, women's-health and pregnancy findings keep reshaping who gets diagnosed and how they're safely treated.
ADHD, autism, and learning differences may sit on one shared spectrum, not in three separate boxes
Using data on more than 10,000 children from the UK’s Twins Early Development Study (tracked at ages 7, 12, and 16), researchers found that traits of ADHD, autism, and learning and language difficulties (including reading, so dyslexia-type traits) load onto a single underlying “neurodevelopmental spectrum” that is strongly inherited, with heritability rising across childhood from roughly 60% to 82%. Picture it less as three separate rooms and more as colors bleeding into one another on a single strip.
Worth knowing because: it supports assessing a child’s whole constellation of traits rather than chasing one diagnostic label, which could help the many kids, and adults, who never fit neatly in one box.
Study: Large sibling study, peer-reviewed
Read it: Molecular Psychiatry (Michelini et al., Jul 2026)
Plain English: Medical Xpress summary
Girls with childhood ADHD carry heavier adult health burdens, and poverty compounds it
A large population study following women born in Wales between 1991 and 1998 through linked health records, found that girls diagnosed with ADHD in childhood were significantly more likely to develop multiple long-term health conditions by early adulthood. When childhood socioeconomic deprivation was also present, the risk more than doubled, and nearly 39% of the excess health burden came from ADHD and deprivation acting together, a one-two punch rather than two separate hits. The most severe pattern, which researchers called “pan-system” multimorbidity, combined physical conditions with complex mental-health diagnoses.
Worth knowing because: it reframes childhood ADHD in girls as an early-warning flag for lifelong physical health, not just a school-years attention issue.
Study: Large population cohort, peer-reviewed
Primary: Nature Mental Health (Wilson et al., 2026)
Press Release: University of Glasgow
ADHD medication in pregnancy and preterm birth: dose seems to matter
This study found early-pregnancy ADHD medication linked to higher preterm-birth risk only with two or more filled prescriptions (about 29% higher), not with a single fill, and in late pregnancy the risk rose with each additional 30 days of cumulative exposure. Context matters: other 2026 reviews find that continuing medication is often safer than stopping, so this is one signal in a mixed, still-forming picture.
Worth knowing because: it gives pregnant patients and clinicians more concrete numbers for a hard risk-benefit conversation, not a reason to stop cold.
Study: Large population cohort, peer-reviewed
Primary: Paediatric and Perinatal Epidemiology (Srinivas, 2026) |
Plain English: free abstract on PubMed (no dedicated lay writeup yet)
Psychedelics for ADHD: “not ready,” scientists caution
Still not ready. The psychedelics-for-ADHD caution we covered last week holds, and this week's coverage is a re-push of the same review, no new data.
A Polish team (Wroclaw Medical University) found only five usable studies on psychedelics for adult ADHD, all small, with different substances, doses, and short follow-ups. The one randomized placebo-controlled trial showed improvement in both the LSD and placebo groups, with no significant edge for LSD. The verdict: the evidence is not there yet to call it a treatment.
Worth knowing because: microdosing is heavily hyped online, and this is a sober reminder that hype is running well ahead of the data.
Study: Early-stage review, limited studies
Primary: International Journal of Molecular Sciences, April 2026
Plain English: Wroclaw Medical University
Hype Watch: centanafadine, pre-launch
The buzz: a new non-stimulant clears its final FDA hurdle on July 24, and the marketing engine is warming up.
The check: the trial data is real, including June's Phase 3b results in adults with ADHD plus anxiety. But "novel" and "approved" are not the same as "right for you." When the ads arrive, read the claims against the published evidence, not the tagline.
Rule of thumb: when a fix is trending faster than it is being replicated, treat the buzz as a hypothesis, not a headline.
ICYMI
Perimenopause hits women with ADHD harder, and earlier
Originally published: September 2025
Iceland's SAGA study (5,392 women, ages 35 to 55) found women with ADHD reported more severe perimenopausal symptoms that began earlier than in women without ADHD. As estrogen and progesterone swing, ADHD traits like fog, impulsivity, and emotional overwhelm tend to flare, like a radio losing signal when the tuning drifts.
Worth knowing because: midlife is when many women are finally diagnosed, and this points to hormones as a real, and potentially treatable, amplifier rather than “just stress.”
Study: Population cohort study, peer-reviewed
Primary: European Psychiatry (Sept 2025), full text: PubMed
Plain English: ADDitude coverage
On the horizon
The FDA’s decision on centanafadine, a first-in-class non-stimulant (a norepinephrine, dopamine, and serotonin reuptake inhibitor), is due July 24, 2026. Otsuka reported positive Phase 3b results (June 25) in adults with ADHD and co-occurring anxiety, a group current meds often struggle with. With a commercial launch approaching, watch the marketing as closely as the data.
Read it: Otsuka Phase 3b results, Jun 2026 | FDA priority-review acceptance, Jan 2026
The one-scroll summary
A modest but real research week. The freshest item is a large UK twin study reframing ADHD, autism, and learning differences as one heritable “neurodevelopmental spectrum,” alongside a newly publicized psychedelics review urging caution. It’s rounded out with substantive women and girls findings on multimorbidity, perimenopause, and pregnancy. The big change to watch is the FDA’s July 24 centanafadine decision.
Know someone who needs this? Forward it.
Keep reading
👉 Browse Every Briefing
Further reading:
ADHD & Sleep | Research Briefing
Connect:
About Me | Blue Sky | Facebook | Instagram | Pinterest | YouTube
The research referenced in this article is intended for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis or treatment.